JP2023539949A5 - - Google Patents
Info
- Publication number
- JP2023539949A5 JP2023539949A5 JP2023537444A JP2023537444A JP2023539949A5 JP 2023539949 A5 JP2023539949 A5 JP 2023539949A5 JP 2023537444 A JP2023537444 A JP 2023537444A JP 2023537444 A JP2023537444 A JP 2023537444A JP 2023539949 A5 JP2023539949 A5 JP 2023539949A5
- Authority
- JP
- Japan
- Prior art keywords
- chemical compound
- compound according
- atom
- group
- alkyl group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073104P | 2020-09-01 | 2020-09-01 | |
| US63/073,104 | 2020-09-01 | ||
| PCT/CA2021/051209 WO2022047579A1 (en) | 2020-09-01 | 2021-09-01 | Halogenated psilocybin derivatives and methods of using |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539949A JP2023539949A (ja) | 2023-09-20 |
| JP2023539949A5 true JP2023539949A5 (https=) | 2024-09-09 |
Family
ID=80492287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023537444A Pending JP2023539949A (ja) | 2020-09-01 | 2021-09-01 | ハロゲン化シロシビン誘導体および使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11998557B2 (https=) |
| EP (1) | EP4208445A4 (https=) |
| JP (1) | JP2023539949A (https=) |
| KR (1) | KR20230062595A (https=) |
| CN (1) | CN116348106A (https=) |
| AU (1) | AU2021337466A1 (https=) |
| CA (1) | CA3191102A1 (https=) |
| IL (1) | IL301026A (https=) |
| MX (1) | MX2023002557A (https=) |
| WO (1) | WO2022047579A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3152752A1 (en) | 2019-10-01 | 2021-04-08 | Thomas Henley | Genetic engineering of fungi to modulate tryptamine expression |
| KR20260008838A (ko) * | 2020-02-18 | 2026-01-16 | 길가메쉬 파마슈티컬스, 인코포레이티드 | 기분 장애 치료에 사용되기 위한 특이적 트립타민 |
| US20240286998A1 (en) * | 2021-06-02 | 2024-08-29 | Saint Joseph's University | Fluorinated tryptamine compounds, analogues thereof, and methods using same |
| CN118984868A (zh) | 2021-12-31 | 2024-11-19 | 恩派瑞安神经科学公司 | 用于产生精神药物生物碱的遗传修饰的生物体 |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| WO2024178504A1 (en) * | 2023-02-27 | 2024-09-06 | Enveric Biosciences Canada Inc. | Tri-halo-alkoxy-substituted tryptamine derivatives and methods of using |
| US12129234B1 (en) | 2023-08-03 | 2024-10-29 | Gilgamesh Pharmaceuticals, Inc. | Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine |
| US12180158B1 (en) | 2023-08-03 | 2024-12-31 | Gilgamesh Pharmaceuticals, Inc. | Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amine |
| WO2025052388A1 (en) * | 2023-09-07 | 2025-03-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Psychedelic compounds, methods of their preparation and uses thereof |
| GB202315025D0 (en) * | 2023-09-29 | 2023-11-15 | Psylink Uab | Production and medical use of psilocybin and related compounds |
| WO2025073360A1 (en) | 2023-10-04 | 2025-04-10 | Enzyan Biocatalysis Gmbh | Biocatalytic cascade for the production of tryptamine derivatives |
| WO2025189271A1 (en) * | 2024-03-15 | 2025-09-18 | Enveric Biosciences Canada Inc. | N-heterocycle substituted tryptamine derivatives and methods of using |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1255199B (it) * | 1992-07-01 | 1995-10-20 | Franco Fraschini | Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani |
| AU679635B2 (en) * | 1994-03-11 | 1997-07-03 | Eli Lilly And Company | Method for treating 5HT-2B receptor related conditions |
| US5688807A (en) * | 1994-03-11 | 1997-11-18 | Eli Lilly And Company | Method for treating 5HT2B receptor related conditions |
| MXPA02005868A (es) * | 1999-12-15 | 2002-10-23 | Syngenta Participations Ag | Composiciones y metodos para reacciones de halogenacion. |
| DE60329607D1 (de) | 2002-06-21 | 2009-11-19 | Suven Life Sciences Ltd | Sich als therapeutische mittel eignende arylalkylindole mit affinität für den serotoninrezeptor, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten |
| WO2004085392A1 (en) * | 2003-03-25 | 2004-10-07 | Faust Pharmaceuticals | Melatonin derivatives and their use for treating neurological dysfunctions |
| US20080171779A1 (en) * | 2007-01-16 | 2008-07-17 | Solvay Pharmaceuticals B.V. | Use of 5-ht6 antagonists to prevent relapse into addiction |
| EP2209380A4 (en) * | 2007-10-09 | 2011-09-14 | Mark T Hamann | METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF |
| CN104276993B (zh) * | 2013-07-12 | 2019-03-15 | 广东东阳光药业有限公司 | 吲哚衍生物及其在药物上的应用 |
| EP3519816A4 (en) * | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| US11261157B2 (en) * | 2016-12-08 | 2022-03-01 | Novatarg, Inc. | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy |
| MA50786A (fr) | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| JP7093961B2 (ja) * | 2018-02-13 | 2022-07-01 | 国立大学法人金沢大学 | ストレス低減薬剤 |
| MX2020009254A (es) * | 2018-03-08 | 2021-01-15 | New Atlas Biotechnologies Llc | Procesos para la produccion de triptaminas. |
| FI129102B (en) * | 2018-03-19 | 2021-07-15 | Teknologian Tutkimuskeskus Vtt Oy | Heterological production of psilosybin |
| EP3999182A1 (en) * | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| CA3160793A1 (en) * | 2019-12-04 | 2021-06-10 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| KR20260008838A (ko) * | 2020-02-18 | 2026-01-16 | 길가메쉬 파마슈티컬스, 인코포레이티드 | 기분 장애 치료에 사용되기 위한 특이적 트립타민 |
| IL301066A (en) | 2020-09-04 | 2023-05-01 | Gilgamesh Pharmaceuticals Inc | Azetidinyl tryptamines and methods for the treatment of psychiatric disorders |
-
2021
- 2021-09-01 AU AU2021337466A patent/AU2021337466A1/en active Pending
- 2021-09-01 EP EP21863150.5A patent/EP4208445A4/en active Pending
- 2021-09-01 CA CA3191102A patent/CA3191102A1/en active Pending
- 2021-09-01 KR KR1020237010996A patent/KR20230062595A/ko active Pending
- 2021-09-01 JP JP2023537444A patent/JP2023539949A/ja active Pending
- 2021-09-01 MX MX2023002557A patent/MX2023002557A/es unknown
- 2021-09-01 IL IL301026A patent/IL301026A/en unknown
- 2021-09-01 WO PCT/CA2021/051209 patent/WO2022047579A1/en not_active Ceased
- 2021-09-01 CN CN202180067808.XA patent/CN116348106A/zh active Pending
-
2022
- 2022-09-06 US US17/903,080 patent/US11998557B2/en active Active
-
2024
- 2024-05-06 US US18/655,793 patent/US12138276B2/en active Active
- 2024-10-08 US US18/909,368 patent/US20250057861A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023539949A5 (https=) | ||
| JP4301571B2 (ja) | 改良された生物学的利用能を有する医薬のプロドラッグ | |
| JP2020189864A5 (https=) | ||
| JP2010525063A (ja) | ヌクレオシドホスホナートが投与された被験者における腎毒性を減少させる方法 | |
| JPH10508858A (ja) | 改良抗ウイルス性プロドラッグ | |
| CA2409613A1 (en) | Methods and compositions for treating hepatitis c virus | |
| CN102906102A (zh) | 含磷活性物的立体选择性合成 | |
| PT674646E (pt) | Derivados lipidicos de fosfonoacidos destinados a ser incorporados nos lipossomas e processo de utilizacao | |
| JPS6254118B2 (https=) | ||
| JP2008523098A5 (https=) | ||
| JP2010501584A5 (https=) | ||
| JP2023543059A5 (https=) | ||
| EA007867B1 (ru) | Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения | |
| JP2023512557A5 (https=) | ||
| JPH0259833B2 (https=) | ||
| JP2021102643A5 (https=) | ||
| JP2025507292A5 (https=) | ||
| JPH05509307A (ja) | プリンの抗ウイルス性ホスホノ―アルケン誘導体 | |
| JP2025118775A5 (https=) | ||
| ES2488821T3 (es) | Proceso de preparación de un compuesto antiviral | |
| JP2023517919A5 (https=) | ||
| JP2006504673A5 (https=) | ||
| JP2022529814A5 (https=) | ||
| JP2006522834A (ja) | ［２−（８，９−ジオキソ−２，６−ジアザビシクロ［５．２．０］ノナ−１（７）−エン−２−イル）アルキル］ホスホン酸および誘導体の鼻腔内投与用医薬組成物およびその使用法 | |
| JP2023513086A (ja) | 炎症性疾患を処置するための胆汁酸－ｇｃｐｉｉ阻害剤コンジュゲート |